Stelexis Therapeutics, founded and solely funded by Deerfield, is a New York-based company on a mission to transform cancer therapeutics and patient care. The company focuses on discovering and developing novel drugs targeting the tumor's origin, specifically pre-cancer and cancer stem cells, which are often responsible for cancer progression and relapse and are typically not eliminated by current treatments.

Notable affiliated individuals include experts in oncology and drug development, supported by Deerfield's investment. Stelexis has made significant strides in identifying previously elusive targets on cancerous stem cells, positioning itself as a pioneer in the field. Their innovative approach has the potential to revolutionize cancer treatment, offering hope for more effective therapies and improved patient outcomes.